Table 3 Posterior probability that each of the PSC risk loci share a causal variant with risk loci from other immune-mediated diseases
From: Fine-mapping and molecular characterisation of primary sclerosing cholangitis genetic risk loci
GWAS Signal | UC | CD | PBC | T1DM | CeD | RhA | MS | SLE | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
Chr | Region | OR | P-value | PP4 | PP4 | PP4 | PP4 | PP4 | PP4 | PP4 | PP4 |
1 | MMEL1 | 1.20 | 5.12⋅10−13 | 0.08 | 0.00 | 0.56 | 0.01 | 0.36 | 0.45 | 0.95 | 0.02 |
2 | BCL2L11 | 1.29 | 2.18⋅10−11 | 0.89 | 0.05 | 0.73 | 0.00 | 0.23 | 0.00 | 0.08 | |
2 | CD28 | 1.25 | 4.12⋅10−16 | 0.06 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | |
3 | MST1 | 1.33 | 5.25⋅10−25 | 0.85 | 0.74 | 0.01 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 |
3 | FOXP1 | 1.44 | 2.80⋅10−15 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
4 | IL2-IL21 | 1.28 | 8.25⋅10−14 | 0.02 | 0.06 | 0.56 | 0.00 | 0.04 | 0.00 | 0.01 | |
6 | BACH2 | 1.21 | 1.09⋅10−09 | 0.01 | 0.07 | 0.04 | 0.18 | 0.49 | 0.87 | 0.00 | 0.02 |
10 | IL2RA | 1.22 | 1.44⋅10−16 | 0.05 | 0.00 | 0.00 | 0.00 | 0.95 | 0.00 | ||
11 | CCDC88B | 1.20 | 1.81⋅10−13 | 0.00 | 0.56 | 0.03 | 0.82 | 0.00 | 0.29 | 0.00 | 0.04 |
12 | SH2B3 | 1.18 | 3.86⋅10−13 | 0.89 | 0.84 | 0.94 | 1.00 | 1.00 | 0.20 | 0.00 | 0.73 |
16 | CLEC16A | 1.20 | 5.22⋅10−13 | 0.00 | 0.00 | 0.57 | 0.61 | 0.00 | 0.00 | 0.05 | |
18 | CD226 | 1.19 | 5.87⋅10−12 | 0.00 | 0.03 | 0.88 | 0.76 | 0.02 | 0.00 | 0.25 | |
19 | PRKD2 | 1.28 | 2.12⋅10−12 | 0.03 | 0.00 | 0.00 | 0.96 | 0.01 | 0.00 | 0.00 | |
21 | ETS2 | 1.23 | 3.40⋅10−13 | 0.82 | 0.79 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
21 | UBASH3A | 1.22 | 2.42⋅10−12 | 0.05 | 0.00 | 0.00 | 0.82 | 1.00 | 0.42 | 0.00 | 0.00 |
